1. Home
  2. NTRA vs TPL Comparison

NTRA vs TPL Comparison

Compare NTRA & TPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • TPL
  • Stock Information
  • Founded
  • NTRA 2003
  • TPL 1888
  • Country
  • NTRA United States
  • TPL United States
  • Employees
  • NTRA N/A
  • TPL N/A
  • Industry
  • NTRA Medical Specialities
  • TPL Oil & Gas Production
  • Sector
  • NTRA Health Care
  • TPL Energy
  • Exchange
  • NTRA Nasdaq
  • TPL Nasdaq
  • Market Cap
  • NTRA 24.9B
  • TPL 21.7B
  • IPO Year
  • NTRA 2015
  • TPL N/A
  • Fundamental
  • Price
  • NTRA $173.27
  • TPL $922.87
  • Analyst Decision
  • NTRA Strong Buy
  • TPL
  • Analyst Count
  • NTRA 17
  • TPL 0
  • Target Price
  • NTRA $192.41
  • TPL N/A
  • AVG Volume (30 Days)
  • NTRA 1.1M
  • TPL 139.6K
  • Earning Date
  • NTRA 11-11-2025
  • TPL 11-05-2025
  • Dividend Yield
  • NTRA N/A
  • TPL 0.67%
  • EPS Growth
  • NTRA N/A
  • TPL 3.18
  • EPS
  • NTRA N/A
  • TPL 20.06
  • Revenue
  • NTRA $1,964,250,000.00
  • TPL $742,873,000.00
  • Revenue This Year
  • NTRA $24.28
  • TPL $18.06
  • Revenue Next Year
  • NTRA $15.22
  • TPL $11.27
  • P/E Ratio
  • NTRA N/A
  • TPL $47.84
  • Revenue Growth
  • NTRA 44.38
  • TPL 10.70
  • 52 Week Low
  • NTRA $117.27
  • TPL $845.56
  • 52 Week High
  • NTRA $183.00
  • TPL $1,769.14
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 59.76
  • TPL 47.91
  • Support Level
  • NTRA $157.43
  • TPL $943.92
  • Resistance Level
  • NTRA $173.62
  • TPL $983.23
  • Average True Range (ATR)
  • NTRA 5.35
  • TPL 31.76
  • MACD
  • NTRA 0.04
  • TPL 2.25
  • Stochastic Oscillator
  • NTRA 67.61
  • TPL 47.39

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About TPL Texas Pacific Land Corporation

Texas Pacific Land Corp is mainly engaged in the sales and leases of land owned, retaining oil and gas royalties, and the overall management of the land owned. It operates its business in two reportable segments; Land and Resource Management and Water Service and Operations. The Land and Resource Management segment focuses on managing surface acres of land and its oil and gas royalty interests, principally concentrated in the Permian Basin. The Water Services and Operations segment encompasses the business of providing full-service water offerings to operators, produced-water treatment, infrastructure development, and disposal solutions. The company generates the majority of its revenue from the Land and Resource Management segment.

Share on Social Networks: